Seres Therapeutics Inc logo

Seres Therapeutics Inc(MCRB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.4
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MCRB

11/13/2026: MCRB (1-star) is currently NOT-A-BUY. Pass it for now.

Seres Therapeutics Inc is a clinical-stage biotechnology stock focused on developing novel microbiome therapeutics for severe bacterial infections and immune disorders. The company's primary strengths lie in its pioneering scientific platform and advanced clinical candidates like SER-155. Its core growth opportunity centers on expanding its pipeline into high-unmet-need indications and securing strategic pharmaceutical partnerships. However, the company faces substantial execution, dilution, and clinical trial risks characteristic of small-cap biotechs. This stock is best suited for speculative growth investors willing to monitor clinical readouts and regulatory updates closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company lacks consistent revenue growth and is currently driven by speculative clinical milestones rather than scaling commercial operations.
Momentum investorStrong fit while signal remains positiveMicro-cap biotechnology stocks can experience sharp short-term price movements upon positive clinical data readouts.
Value investorWeak fitUnprofitable operations and persistent cash burn make traditional value metrics unsupportive.
Dividend investorWeak fitThe company pays no dividends and retains all capital for clinical trials.
Low-risk investorWeak fitHigh clinical, regulatory, and financial volatility expose investors to significant capital loss risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow share price and micro-cap status cause dramatic intraday swings based on news flow.
Valuation riskHighValuation is purely speculative and tied to binary clinical outcomes.
Competition risk (biotech and microbiome drug developers)Medium / highFierce competition from alternative biopharma therapies threatens commercial relevance.
Business qualityLowEarly-stage pipeline status lacks established commercial earnings quality.
Dividend incomeLow / noneNo dividend is paid or anticipated.
Execution riskHighClinical trial delays or failures could threaten company survival.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.27M USD
Price to earnings Ratio -
1Y Target Price 17
Price to earnings Ratio -
1Y Target Price 17
Volume (30-day avg) 83.4K shares
Beta 0.56
52 Weeks Range 1.30 - 29.98
Updated Date 11/15/2026
52 Weeks Range 1.30 - 29.98
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -5.01

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -62.3%
Avg. Invested days 14
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MCRB receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
MCRB has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+103.9%) and strong cash generation (FCF margin 109.6%) are partially offset by slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
MCRB's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 21.7%). Operating efficiency is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is MCRB's strongest growth driver at +103.9% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+100.6%, strong) is also strong, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 22.1% and approximately 88.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 11.20% supports management-shareholder alignment.

Top 5 Institutional Investors

Flagship Ventures Management, Inc. 11.50%
Vanguard Capital Management, LLC 2.86%
Marshall Wace Asset Management Ltd 1.71%
Vontobel Holding Ltd. 1.22%
BlackRock Inc 1.10%

Unit Economics (Per $1K Revenue)

★★★★★
MCRB generates approximately $-4,238 of gross profit, $-119,101 of operating income, and $1,096 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses explain the 2-star rating, with moderate cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
MCRB has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Research and LicensingCollaborations, research grants, milestone payments, and potential future licensing royalties from microbiome drug candidates.The company currently generates little commercial product revenue, relying instead on potential partnership milestones and external funding.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 10.82
Enterprise Value 32.52M
Price to Sales(TTM) 6.72
Enterprise Value 32.52M
Price to Sales(TTM) 6.72
Enterprise Value to Revenue 41.21
Enterprise Value to EBITDA 0.89
Shares Outstanding 10.20M
Shares Floating 8.99M
Shares Outstanding 10.20M
Shares Floating 8.99M
Percent Insiders 11.2
Percent Institutions 22.15

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.